The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Isis Pharmaceuticals competitive analysis

Loading summary...

Latest patents of Isis Pharmaceuticals opposed by its competitors

Explore Isis Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP2906696
Dec 14, 2022Methods For Modulating C9Orf72 Expression2
EP2742135
Jun 10, 2020Linkage Modified Gapped Oligomeric Compounds And Uses Thereof1
EP2399588
Apr 29, 2020Nucleoside Derivatives As Inhibitors Of Rna-Dependent Rna Viral Polymerase1
EP2640853
Dec 26, 2018Modulation Of Alpha Synuclein Expression1
EP2864479
Aug 15, 2018Modulation Of Ube3A-Ats Expression1
EP2701713
Feb 7, 2018Modulation Of Apolipoprotein Ciii (Apociii) Expression2
EP2812342
Nov 15, 2017Modulation Of Rna By Repeat Targeting1

Latest PTAB cases involving Isis Pharmaceuticals

Discover the latest PTAB cases involving Isis Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Isis Pharmaceuticals with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ISIS PHARMACEUTICALS - 9 - -
HOFFMANN EITLE148 - - -
ROCHE372534
STRAWMAN339 - - -